ASRT Assertio Holdings, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ASRT Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$11.66
Analyst Target
$37.44
+221.1%
Upside
52W High
$15.15
52W Low
$7.65
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 28, 2026
Market cap
$74.82M
P/E
N/A
ROE
-24.5%
Profit margin
-21.1%
Debt/Equity
0.38
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ASRT's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and inconsistent earnings performance. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given negative earnings and high revenue volatility. Despite strong revenue growth (69.4% YoY) and a low price-to-sales ratio (0.54), the company trades at a significant discount due to deep operational losses and poor capital efficiency. Insider selling activity and a 5-year price decline of 80.4% further undermine confidence. The stock's current valuation appears unsustainable without a clear path to sustained profitability.
Key Strengths
69.4% YoY revenue growth indicates strong top-line momentum
High gross margin of 65.47% suggests strong pricing power or cost control
Low price-to-sales ratio (0.54) implies potential undervaluation on a revenue basis
Positive operating margin (28.72%) indicates operational efficiency despite net losses
Low debt-to-equity ratio (0.38) reflects conservative capital structure
Key Risks
Piotroski F-Score of 2/9 signals extreme financial weakness and distress
Negative ROE (-24.48%) and ROA (-4.17%) indicate poor return on capital
Persistent net losses (profit margin -21.06%) and inconsistent earnings surprises
Insider selling activity (1 sale, 0 buys) suggests lack of confidence from management
No analyst consensus or target price data undermines market conviction
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
34
Weak
55
70
25
20
0
AI Verdict
Weak
Key drivers: Low Piotroski F-Score (2/9), Negative profitability and returns, High earnings volatility, Weak insider sentiment, Poor long-term price performance
Confidence
90%
Value
55/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 0.54 is below industry average
- Low Price/Book (0.71) suggests potential asset-based undervaluation
Watchpoints
- No Graham Number or intrinsic value due to negative earnings
- Forward P/E of 7.77 is misleading without sustainable earnings
- High revenue growth not translating into profitability
Future
70/100
Ref Growth rates
Positives
- 69.4% YoY revenue growth is exceptional
- Recent Q/Q EPS growth of +800% signals potential turnaround
Watchpoints
- Earnings growth is not available (N/A) despite revenue growth
- Historical earnings volatility undermines reliability of future projections
- No clear path to sustained profitability
Past
25/100
Ref Historical trends
Positives
- Some quarters show large positive earnings surprises (e.g., +500%)
- Recent quarters show improvement in EPS vs. prior expectations
Watchpoints
- Five of the last 25 quarters reported negative earnings surprises
- Historical EPS has been highly erratic (e.g., -1104.5% surprise in 2020)
- 5-year price decline of 80.4% reflects long-term underperformance
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity of 0.38 is low and conservative
- Current and quick ratios (1.58, 1.41) indicate short-term liquidity
Watchpoints
- Piotroski F-Score of 2/9 is extremely low, indicating financial distress
- Negative ROE and ROA suggest poor capital allocation
- No Altman Z-Score available, but low F-Score implies distress risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- Company is not generating profits to support dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$11.66
Analyst Target
$37.44
Upside/Downside
+221.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ASRT and closest competitors.
Updated 2026-02-27
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ASRT
Assertio Holdings, Inc.
Primary
|
-80.4% | -85.9% | -2.8% | -7.5% | -1.3% | -1.5% |
|
AMWL
American Well Corporation
Peer
|
-99.3% | -93.4% | -55.6% | -45.6% | +6.1% | +3.4% |
|
ATHE
Alterity Therapeutics Limited
Peer
|
-80.8% | -8.5% | +6.3% | -45.8% | +14.5% | +2.9% |
|
BDSX
Biodesix, Inc.
Peer
|
-97.8% | -75.2% | -34.9% | +31.6% | +72.1% | +49.0% |
|
ALGS
Aligos Therapeutics, Inc.
Peer
|
-98.8% | -77.7% | -26.4% | -25.8% | +1.5% | +8.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
7.77
PEG Ratio
N/A
P/B Ratio
0.71
P/S Ratio
0.54
EV/Revenue
0.16
EV/EBITDA
1.98
Market Cap
$74.82M
Profitability
Profit margins and return metrics
Profit Margin
-21.06%
Operating Margin
28.72%
Gross Margin
65.47%
ROE
-24.48%
ROA
-4.17%
Growth
Revenue and earnings growth rates
Revenue Growth
+69.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.38
Low debt
Current Ratio
1.58
Good
Quick Ratio
1.41
Good
Cash/Share
$14.56
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-09
$N/A
2025-11-10
$2.7
2025-08-11
$0.3
+500.0% surprise
2025-05-12
$-0.6
-300.0% surprise
Healthcare Sector Comparison
Comparing ASRT against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-24.48%
This Stock
vs
-52.77%
Sector Avg
-53.6%
(Below Avg)
Profit Margin
-21.06%
This Stock
vs
-20.78%
Sector Avg
+1.4%
(Better)
Debt to Equity
0.38
This Stock
vs
6.16
Sector Avg
-93.8%
(Less Debt)
Revenue Growth
69.4%
This Stock
vs
137.39%
Sector Avg
-49.5%
(Slower)
Current Ratio
1.58
This Stock
vs
3.36
Sector Avg
-53.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ASRT
Assertio Holdings, Inc.
|
BEARISH | $74.82M | - | -24.5% | -21.1% | $11.66 | |
|
AMWL
American Well Corporation
|
BEARISH | $79.73M | - | -37.0% | -42.8% | $4.87 | |
|
ATHE
Alterity Therapeutics Limited
|
BEARISH | $64.35M | - | -43.2% | -223.3% | $3.55 | |
|
BDSX
Biodesix, Inc.
|
BEARISH | $93.92M | - | -302.6% | -49.3% | $11.74 | |
|
ALGS
Aligos Therapeutics, Inc.
|
BEARISH | $46.58M | - | -196.9% | -% | $7.57 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-10 | STARK DAVID MATTHEW | Director | Sale | 8,959 | $6,806 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
4 analysts
HC Wainwright & Co.
2026-01-05
Buy
Buy
Past News Coverage
Recent headlines mentioning ASRT from our newsroom.
Newest → oldest
No matching news yet.